Skip to main content
PMC home page
Heart logoLink to Heart
. 2002 Oct;88(Suppl 2):ii15–ii22. doi: 10.1136/heart.88.suppl_2.ii15

Preventing clinical heart failure: the rationale and scientific evidence

D Wood
PMCID: PMC1876271  PMID: 12213795

Full Text

The Full Text of this article is available as a PDF (226.9 KB).

Figure 1 .

Figure 1

Open in a new tab

Incidence of heart failure in the population. Modified from Cowie et al.1

Figure 2 .

Figure 2

Open in a new tab

Final aetiology of heart failure in 136 cases aged less than 75 years using angiographic and myocardial perfusion data (where available). AF, atrial fibrillation; CAD, coronary artery disease. Reproduced from Fox et al,3 with permission.

Figure 3 .

Figure 3

Open in a new tab

Survival of 552 incident cases of heart failure, from the London heart failure studies (with 95% confidence intervals). Modified from Cowie et al.2

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Colhoun H. M., Dong W., Barakat M. T., Mather H. M., Poulter N. R. The scope for cardiovascular disease risk factor intervention among people with diabetes mellitus in England: a population-based analysis from the Health Surveys for England 1991-94. Diabet Med. 1999 Jan;16(1):35–40. doi: 10.1046/j.1464-5491.1999.00017.x. [DOI] [PubMed] [Google Scholar]
  2. Colhoun H. M., Dong W., Poulter N. R. Blood pressure screening, management and control in England: results from the health survey for England 1994. J Hypertens. 1998 Jun;16(6):747–752. doi: 10.1097/00004872-199816060-00005. [DOI] [PubMed] [Google Scholar]
  3. Cowie M. R., Wood D. A., Coats A. J., Thompson S. G., Poole-Wilson P. A., Suresh V., Sutton G. C. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999 Mar;20(6):421–428. doi: 10.1053/euhj.1998.1280. [DOI] [PubMed] [Google Scholar]
  4. Cowie M. R., Wood D. A., Coats A. J., Thompson S. G., Suresh V., Poole-Wilson P. A., Sutton G. C. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000 May;83(5):505–510. doi: 10.1136/heart.83.5.505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Exner D. V., Dries D. L., Waclawiw M. A., Shelton B., Domanski M. J. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1999 Mar 15;33(4):916–923. doi: 10.1016/s0735-1097(98)00675-5. [DOI] [PubMed] [Google Scholar]
  6. Fox K. F., Cowie M. R., Wood D. A., Coats A. J., Gibbs J. S., Underwood S. R., Turner R. M., Poole-Wilson P. A., Davies S. W., Sutton G. C. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J. 2001 Feb;22(3):228–236. doi: 10.1053/euhj.2000.2289. [DOI] [PubMed] [Google Scholar]
  7. Kjekshus J., Pedersen T. R., Olsson A. G., Faergeman O., Pyörälä K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail. 1997 Dec;3(4):249–254. doi: 10.1016/s1071-9164(97)90022-1. [DOI] [PubMed] [Google Scholar]
  8. Køber L., Torp-Pedersen C., Carlsen J. E., Bagger H., Eliasen P., Lyngborg K., Videbaek J., Cole D. S., Auclert L., Pauly N. C. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995 Dec 21;333(25):1670–1676. doi: 10.1056/NEJM199512213332503. [DOI] [PubMed] [Google Scholar]
  9. Moser M., Hebert P. R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996 Apr;27(5):1214–1218. doi: 10.1016/0735-1097(95)00606-0. [DOI] [PubMed] [Google Scholar]
  10. Pfeffer M. A., Braunwald E., Moyé L. A., Basta L., Brown E. J., Jr, Cuddy T. E., Davis B. R., Geltman E. M., Goldman S., Flaker G. C. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992 Sep 3;327(10):669–677. doi: 10.1056/NEJM199209033271001. [DOI] [PubMed] [Google Scholar]
  11. Rodeheffer R. J., Jacobsen S. J., Gersh B. J., Kottke T. E., McCann H. A., Bailey K. R., Ballard D. J. The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc. 1993 Dec;68(12):1143–1150. doi: 10.1016/s0025-6196(12)60063-9. [DOI] [PubMed] [Google Scholar]
  12. Senni M., Tribouilloy C. M., Rodeheffer R. J., Jacobsen S. J., Evans J. M., Bailey K. R., Redfield M. M. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998 Nov 24;98(21):2282–2289. doi: 10.1161/01.cir.98.21.2282. [DOI] [PubMed] [Google Scholar]
  13. Shumway N. E. Cardiac transplantation. J Am Coll Cardiol. 1993 Jul;22(1):6–7. doi: 10.1016/0735-1097(93)90809-f. [DOI] [PubMed] [Google Scholar]
  14. Vantrimpont P., Rouleau J. L., Wun C. C., Ciampi A., Klein M., Sussex B., Arnold J. M., Moyé L., Pfeffer M. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol. 1997 Feb;29(2):229–236. doi: 10.1016/s0735-1097(96)00489-5. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES